Logo
x

Search

Subscribe Now

Nurix Therapeutics

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

Nurix Therapeutics’ NX-5948 Secures the EMA’s PRIME Designation for Treating R/R Chronic Lymphocytic Leukemia

  • November 21, 2024
Nurix Therapeutics Receives the US FDA’s IND Clearance for NX-1607 to Treat Advanced Malignancies

Nurix Therapeutics Receives the US FDA’s IND Clearance for NX-1607 to Treat Advanced Malignancies

  • July 4, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.